24.08.2013 Views

Abstract book - ESPRAS

Abstract book - ESPRAS

Abstract book - ESPRAS

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

L9. Malignant melanoma. Contemporary diagnostic<br />

procedures,treatment, and perspectives for the future<br />

Prof. Krzysztof Drzewiecki<br />

Department of Plastic Surgery, Rigshospitalet University Hospital<br />

Copenhagen, Denmark<br />

Cutaneous Malignant Melanoma (CMM) comprises 3% of all malignancies.<br />

The incidence rate has tripled during the last 40 years. Middle-aged persons<br />

are most often hit by this tumour. Females are slightly overrepresented. UVspectrum<br />

of sunlight is the most important external ethiological factor.<br />

Constitutional predisposing factors are freckled persons, who are sensitive to<br />

sunshine, persons with many naevi and congenital naevi. 4-10% of patients<br />

with CMM report about other single cases of CMM in their families.<br />

However, in less than 1% of the melanoma cases a gene defect can be<br />

detected. Dermatoscopy and SIA-scopy enhance the probability of a correct<br />

clinical diagnosis, provided the doctor is accustomed with this method.<br />

Clinical examination, sentinel node procedure, and microscopy are necessary<br />

to classify a CMM correctly – before the treatment. The American Joint<br />

Committee on Cancer (AJCC) has a staging system based on a TNM<br />

assessment, which should be used<br />

The standard treatment of CMM is surgery for primary lesion, surgery for<br />

secondary regional lymph node deposits and surgery when ever technically<br />

possible for distant metastases. Hypertherm Regional Perfusion treatment for<br />

regional metastases on the extremities is widely accepted. X-ray treatment is<br />

used for CMM metastases that are not accessible for surgery. Chemotherapy,<br />

biological modifiers and vaccines should only be used as part of a clinically<br />

controlled study, because they are experimental treatments. Interferons and<br />

vaccines are used in a clinical experimental setting as an adjuvant therapy<br />

following surgery in suitable patients.<br />

L10. Functional free flaps reconstruction<br />

Prof. Milomir Ninković<br />

Department of Plastic, Reconstructive and Hand Surgery, Burn Centre,<br />

Technical University - Hospital Bogenhausen, Munchen, Germany<br />

The transfer of a free microvascular flap is a well-established method in the<br />

reconstructive surgery. It provides tissue with a rich blood supply, which<br />

improves healing process, its resistance to infections, and quality of<br />

reconstruction. The technique settles freedom in flap design for optimal<br />

contour in accordance with size and shape of the defect.<br />

The timing of free tissue transfer after upper extremities injury seems to be a<br />

very important issue. The free flap closure can be divided according to time of<br />

reconstruction into three categories: primary free flap closure (within 24h),<br />

delayed primary free flap closure (2-7 days, and secondary free flap closure<br />

(after one week).<br />

Many factors besides timing of closure and the success of flap survival alone<br />

influence the functional outcome of the upper extremity reconstruction. For<br />

instance severity of injury, particular the nerve and muscle damaged, as well as<br />

length of bone loss etc.<br />

In this presentation all factors which influence the final result of upper<br />

extremity are discussed and principles of treatment are defined.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!